Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 5Sarcoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Fallopian Tube Neoplasms 2Vulvar Neoplasms 1Recurrence 1Neuroendocrine Tumors 1Neoplasms 1Liver Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Disease 1Colorectal Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1Advanced Adult Hepatocellular Carcinoma 1

Interventions

Oxaliplatin 18Surveys and Questionnaires 15Fluorouracil 15Capecitabine 13Leucovorin 12Blood Specimen Collection 11Irinotecan 10Standard of Care 7Cisplatin 7Endoscopic Mucosal Resection 6atezolizumab 5Specimen Handling 5Radiotherapy 5Educational Status 5Drug Therapy 5Docetaxel 5S 1 (combination) 4Radiosurgery 4Nivolumab 4Magnetic Resonance Spectroscopy 4Interviews as Topic 4Gemcitabine 4Everolimus 4Colonoscopy 4Biopsy 4Bevacizumab 4tegafur-gimeracil-oteracil 3pemigatinib 3apatinib 3Remote Patient Monitoring 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastrointestinal Neoplasms × tivozanib × Clear all
NCT01058655 2017-04-13

RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer

Dana-Farber Cancer Institute

Phase 1/2 Completed
56 enrolled 15 charts
Gastrointestinal

Gastrointestinal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡